Mumbai: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter and fiscal year ending March 31, 2021. These audited results were taken on record by the Board of Directors at a meeting held today. The Board recommended a dividend of 325%.
Financial Highlights (from Continuing Operations) – Consolidated IND-AS
Amt in INR mn
|Q4 FY2021||Q3 FY2021||QoQ Growth %||Q4 FY2020||YoY Growth %||FY2021||FY2020||YoY Growth %|
|Sales||37,593||39,173||4.0%||37,910|| 0.8%||149,270||151,428||– 1.4%|
|EBITDA before Forex & Other Income||7,075||8,064|| 12.3%||5,237||35.1%||26,578||23,633||12.5%|
|EBITDA Margin (%)||18.8%||20.6%|| 180 bps||13.8%||500 bps||17.8%||15.6%||220 bps|
|PBT before Exceptional items||5,182||5,247|| 1.2%||4,123||25.7%||16,751||15,054||11.3%|
|PBT after Exceptional Items||5,182||5,247|| 1.2%||4,954||NA||16,751||7,533||NA|
Income Statement highlights – Q4 FY2021
- Gross Profit was INR 24,417 mn compared to INR 25,423 mn in Q3 FY2021, with gross profit margin of 65.0%
- EBIDTA adjusted for forex and other income was 18.8% of sales, compared to 18.6% in Q3FY2021 excluding the
one-time settlement income forming part of other operating income
- Personnel cost was 17.0% of sales at INR 6,402 mn compared to INR 7,068 mn in Q3 FY2021
- Manufacturing and other expenses were 29.7% of sales at INR 11,178 mn compared to INR 11,569 mn in Q3
- Investment in R&D for the quarter was INR 3,427 mn (9.1% of sales)
Balance Sheet highlights
- Operating working capital was INR 62,136 mn as on March 31, 2021
- Capital Expenditure for the quarter was INR 1,396 mn, and for the full year was INR 6,276 mn
- Net Debt as on March 31, 2021 stands at INR 6,626 mn
- Net Debt-Equity for the company stands at 0.05 as on March 31, 2021
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are happy that the journey to sustain margin improvement continues, despite a challenging environment. On the back of a strong ramp-up of inline products and meaningful new product launches, we are confident of a solid growth trajectory and continued margin expansion. Ensuring the safety of our employees while maintaining business continuity is a key priority at this time.”
Consolidated Financial Results – Q4 FY2021
Amt in INR mn
|Particulars||Q4 FY2021||% of sales||Q3 FY2021||% of sales||QoQ Growth %||Q4 FY2020||% of sales||YoY Growth %|
|Other operating income||238||0.6%||1,001||2.6%||-76.2%||547||1.4%||-56.5%|
|Total Revenue from operations||37,831||100.6%||40,174||102.6%||-5.8%||38,457||101.4%||-1.6%|
|Gross Profit (Excl. Other op. income)||24,417||65.0%||25,423||64.9%||-4.0%||23,860||62.9%||2.3%|
|Manufacturing & Other expenses||11,178||29.7%||11,569||29.5%||-3.4%||11,519||30.4%||-3.0%|
|Depreciation, Amortization & Impairment Expense||2,157||5.7%||2,44||6.2%||-11.7%||2,142||5.7%||0.7%|
|PBT before Exceptional items||5,182||13.8%||5,247||13.4%||-1.2%||4,123||10.9%||25.7%|
|PBT after Exceptional items||5,182||13.8%||5,247||13.4%||-1.2%||4,954||13.1%||4.6%|
|Profit after Tax||4,642||12.3%||4,412||11.3%||5.2%||3,903||10.3%||18.9%|
|(+) Share of Profit from JV||2||0.0%||2||0.0%||0%||10||0.0%||-80.0%|
|(-) Non-Controlling Interest||40||0.1%||31||0.1%||29.0%||17||0.0%||35.3%|
|Profit/(Loss) for the period||4,604||12.2%||4,383||11.2%||5.0%||3,896||10.3%||18.2%|
Consolidated Financial Results – FY2021
Amt in INR mn
|Particulars||FY2021||% of sales||FY2020||% of sales||YoY Growth %|
|Other operating income||2,360||1.6%||2,320||1.5%||1.7%|
|Total Revenue from operations||51,630||101.6%||153,748||101.5%||-1.4%|
|Gross Profit (Excl. Other op. income)||95,648||64.1%||97,122||64.1%||-1.5%|
|Manufacturing & Other expenses||44,080||29.5%||46,025||30.4%||-4.2%|
|Depreciation, Amortization & Impairment Expense||8,874||5.9%||9,703||6.4%||–8.5%|
|PBT before Exceptional items||16,751||11.2%||15,054||9.9%||11.3%|
|PBT after Exceptional items||16,751||11.2%||7,533||5.0%||NA|
|Profit after Tax||12,266||8.2%||(4,038)||-2.7%||NA|
|(+) Share of Profit from JV||13||0.0%||39||0.0%|
|(-) Non-Controlling Interest||114||0.1%||(4)||0.0%||NA|
|Net Profit from continuing operations||12,165||8.1%||(3,995)||-2.6%||NA|
|Profit/(Loss) from discontinued operations||0||NA||1,301||0.9%||NA|
|Profit/(Loss) for the period||12,165||8.1%||(2,694)||-1.8%||NA|
|Particulars||Q4 FY2021||Q3FY2021||Growth QoQ||Q4FY2020||Growth YoY|
|Total Product Sales||149,270||149,987||-0.5%|
|NCE Licensing Income||–||1,441||NA|
Lupin’s North America sales for FY2021 were INR 55,520 mn compared to INR 58,212 mn in FY 2020; accounting for 37% of Lupin’s global sales. Q4 FY2021 sales were INR 14,952 mn, up 3.7% compared to INR 14,424 mn during Q3 FY2021 and sales of INR 15,791 mn during Q4 FY2020.
- For the U.S. market, FY2021 sales were USD 720 mn compared to USD 800 mn in FY2020
- Q4 FY2021 sales were USD 195 mn compared to USD 188 mn during Q3 FY2021 and USD 212 mn during Q4 FY2020
- The Company filed 9 ANDAs during the quarter and received 6 ANDA approval from the U.S. FDA
- The Company launched 3 products during the quarter in the US market. The Company now has 168 products in the U.S. generics market.
- Lupin continues to be the 3rd largest pharmaceutical player in both U.S. generic market and US total market by prescriptions (IQVIA MAT March 2021)
- Lupin is now the market leader in 53 products in the U.S. generics market and amongst the Top 3 in 122 of its marketed products (market share by prescriptions, IQVIA March 2021)
Lupin’s India formulation sales for FY2021 were INR 52,712 mn, up 2.6% as compared to INR 51,385 mn in FY2020; accounting for 35% of Lupin’s global sales. Q4 FY2021 sales were INR 12,866 mn, compared to sales of INR 13,669 mn during Q3 FY2021 and up 7.9% compared to sales of INR 11,920 mn during Q4 FY2020.
Lupin is the 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2021).
Growth Markets (LATAM and APAC)
Lupin’s LATAM & APAC regions together form its Growth Markets. Growth Markets sales for FY2021 were INR 11,964 mn, compared to INR 12,212 mn in FY2020; accounting for 8% of Lupin’s global sales. Q4 FY2021 sales were INR 3,033 mn, compared to sales of INR 3,314 mn during Q3 FY2021 and up 8.3% as compared to sales of INR 2,800 mn during Q4 FY2020.
Lupin’s Brazil sales were BRL 239 mn for FY2021, compared to a sales of BRL 177 mn for FY2020. Q4 FY2021 sales were BRL 59 mn, compared to BRL 66 mn during Q3 FY2021 and BRL 37 mn during Q4 FY2020.
Lupin’s Mexico sales were MXN 621 mn for FY2021, compared to a sales of MXN 691 mn for FY2020. Q4 FY2021 sales were MXN 154 mn, compared to MXN 188 mn during Q3 FY2021 and MXN 171 mn during Q4 FY2020.
Lupin’s Philippines sales were PHP 1,388 mn for FY2021, compared to a sales of PHP 1,874 mn for FY2020. Q4 FY2021 sales were PHP 402 mn, compared to PHP 367 mn during Q3 FY2021 and PHP 522 mn during Q4 FY2020.
Lupin’s Australia sales were AUD 57 mn for FY2021, compared to a sales of AUD 48 mn for FY2020. Q4 FY2021 sales were AUD 14.2 mn, compared to AUD 15.7 mn during Q3 FY2021 and AUD 13.0 mn during Q4 FY2020.
Europe, Middle-East and Africa (EMEA)
Lupin’s EMEA sales for FY2021 were INR 12,781 mn, up 3.4% as compared to INR 12,364 mn in FY 2020; accounting for 9% of Lupin’s global sales. Q4 FY2021 sales were INR 3,749 mn, up 14.6% compared to sales of INR 3,272 mn during Q3 FY2021 and up 2.7% as compared to sales of INR 3,650 mn during Q4 FY2020.
Lupin’s South Africa sales were ZAR 1,295 mn for FY2021, compared to a sales of ZAR 1,219 mn for FY2020. Q4 FY2021 sales were ZAR 431 mn, compared to ZAR 323 mn during Q3 FY2021 and ZAR 374 mn during Q4 FY2020.
Lupin is the 4th largest generic player in the South African market by prescription (IQVIA February 2021).
Lupin’s Germany sales were EUR 29.2 mn for FY2021, compared to a sales of EUR 36.2 mn for FY2020. Q4 FY2021 sales were EUR 5.4 mn, compared to EUR 8.1 mn during Q3 FY2021 and EUR 9.3 mn during Q4 FY2020. 3 FY2021 were EUR 8.1 mn, compared to EUR 8.1 mn during Q2 FY2021 and EUR 9.5 mn during Q3 FY2020.
Lupin’s Global API sales for FY2021 were INR 13,823 mn, up 6.3% as compared to INR 12,999 mn in FY 2020; accounting for 9% of Lupin’s global sales. Q4 FY2021 sales were INR 2,556 mn, compared to sales of INR 3,438 mn during Q3 FY2021 and sales of INR 3,286 mn during Q4 FY2020.
Research and Development
Investment in R&D for continued operations amounted to INR 14,324 mn (9.6% of sales) for FY2021 and INR 3,427 mn (9.1% of sales) for Q4 FY2021.
Lupin received approval for 6 ANDA from the U.S. FDA during the quarter. Cumulative ANDA filings with the US FDA stood at 437 as of March 31, 2021, with the company having received 288 approvals to date.
The Company now has 45 First-to-Files (FTF) filings including 16 exclusive FTF opportunities. Cumulative DMF filings stand at 201 as of March 31, 2021.
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and MiddleEast regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. In FY2021, the Company invested 9.6% of its revenues on research and development.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on
For further information or queries please contact –
Head – Investor Relations / Corporate M&A
Tel: +91-22 6640 8237
Head – Corporate Communications
Tel: +91-22-6640 2532